The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 15, 2017

Filed:

Nov. 30, 2015
Applicant:

Oncomed Pharmaceuticals, Inc., Redwood City, CA (US);

Inventors:

Austin Gurney, San Francisco, CA (US);

John Lewicki, Los Gatos, CA (US);

Sanjeev H. Satyal, San Carlos, CA (US);

Timothy Hoey, Hillsborough, CA (US);

Assignee:

ONCOMED PHARMACEUTICALS, INC., Redwood City, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 14/705 (2006.01); A61K 38/00 (2006.01); A61K 45/06 (2006.01); A61K 47/48 (2006.01); C07K 14/72 (2006.01); C07K 16/00 (2006.01); C07K 16/18 (2006.01); C07K 16/28 (2006.01); G01N 33/574 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 14/705 (2013.01); A61K 45/06 (2013.01); A61K 47/48276 (2013.01); A61K 47/48369 (2013.01); C07K 14/723 (2013.01); C07K 16/00 (2013.01); C07K 16/18 (2013.01); C07K 16/28 (2013.01); G01N 33/57423 (2013.01); G01N 33/57492 (2013.01); A61K 38/00 (2013.01); A61K 2039/505 (2013.01); C07K 2319/30 (2013.01); C07K 2319/33 (2013.01);
Abstract

The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides a soluble FZD receptor comprising an extracellular domain of a human FZD receptor that inhibits growth of tumor cells. The present invention still further provides a soluble receptor comprising a Fri domain of a human FZD receptor that binds a ligand of a human FZD receptor and said soluble receptor is capable of inhibiting tumor growth. The present invention still further provides a method of treating cancer comprising administering a soluble FZD receptor comprising for example, either an extracellular domain of a human FZD receptor or a Fri domain of a human FZD receptor, in an amount effective to inhibit tumor growth.


Find Patent Forward Citations

Loading…